The Research Snapshot
A new clinical analysis published in Psychiatric Times (April 2026) is pushing the mental health field toward more aggressive, data-informed management of treatment-resistant depression (TRD) — specifically when using NMDA receptor antagonists like ketamine and esketamine. The core message from clinicians: stop waiting and watching. Optimize doses faster, switch formulations sooner when a patient isn't responding, and use standardized tools like the PHQ-9 to track both symptom improvement and side-effect burden in real time.
The piece focuses on the full class of NMDA antagonists — which includes IV ketamine, intramuscular ketamine, intranasal esketamine (Spravato), sublingual troches, and oral ketamine tablets — and compares their tolerability profiles and reasons patients discontinue treatment. What emerges is a nuanced picture: side effects across this drug class are real and worth tracking carefully, but they are also manageable, often transient, and highly route-dependent.
Side Effects by the Numbers: What Makes Patients Stop
Across NMDA antagonist treatments, the most commonly reported side effects include dissociation, dizziness, nausea, sedation, and transient blood pressure elevation. Dissociative symptoms — feelings of depersonalization, perceptual distortion, or a floating sensation — are the most distinctive and, for many patients, the most unfamiliar. Importantly, these effects are typically dose-dependent and peak during or shortly after administration, making the delivery route and absorption profile a critical variable.
Discontinuation rates vary meaningfully across formulations. Intravenous infusion protocols, while delivering predictable plasma levels, require clinic visits every few days and carry a higher administrative burden — a common driver of dropout unrelated to side effects. Intranasal esketamine (Spravato) has formal FDA-monitored REMS requirements, meaning patients must observe and wait on-site for two hours post-dose, which creates its own access and adherence friction. Oral and sublingual ketamine, by contrast, offer home-based dosing in many programs — a structural advantage for patients who find clinic travel difficult or who experience anxiety around clinical environments.
The Psychiatric Times analysis reinforces that tracking why patients discontinue — side-effect intolerance versus logistical barriers versus lack of efficacy — is essential for improving real-world outcomes. Too often, patients quietly stop treatment without a documented clinical reason, leaving prescribers without the data to course-correct.
Where Oral Ketamine Tablets Fit In This Picture
For patients on oral ketamine tablets, the side-effect profile looks somewhat different from IV or nasal routes, and that difference matters for both expectations and adherence.
Oral bioavailability of ketamine is approximately 20–25%, compared to roughly 45–50% for sublingual troches and near-100% for IV infusion. This lower absorption means oral tablets generally produce a milder dissociative experience — which is a genuine tolerability advantage for patients who found higher-bioavailability routes overwhelming. The trade-off is that therapeutic plasma concentrations require higher milligram doses by mouth, and the onset is slower and more gradual (typically 30–60 minutes), making titration a more patient process.
This slower, gentler onset can actually reduce the acute side-effect burden that drives discontinuation in clinical settings. Patients on oral tablets are less likely to experience the abrupt, intense dissociation sometimes associated with IV infusions — the kind that can feel alarming without clinical support nearby. That said, oral dosing introduces its own variables: food intake, gut motility, and first-pass liver metabolism all affect how much ketamine actually reaches the bloodstream. A dose taken with a full meal may absorb quite differently than the same dose on an empty stomach, producing inconsistent effects that can frustrate both patients and providers trying to titrate optimally.
The clinical advice emerging from this analysis — optimize doses faster, don't let patients languish at a sub-therapeutic dose out of excessive caution — applies directly to oral tablet protocols. If a patient is three or four weeks in and their PHQ-9 scores haven't moved, staying the course at the same dose is not a neutral choice. It's a missed window. Escalating the dose, adjusting timing, or revisiting fasting instructions can make a meaningful difference before considering a formulation switch.
What PHQ-9 Tracking Means in Practice
The Psychiatric Times piece specifically calls out PHQ-9 tracking as an underutilized tool in ketamine management. The PHQ-9 is a nine-item validated depression scale that patients can complete in minutes — and it produces a numeric score that makes side-effect-to-benefit tradeoffs legible over time.
For oral ketamine patients, consistent PHQ-9 logging (ideally weekly, or at minimum before and after each dosing cycle) creates a paper trail that helps clinicians see whether the treatment is actually working — separate from subjective impressions. It also provides context for side-effect reports. A patient who is experiencing dizziness but whose PHQ-9 has dropped from 18 to 9 is in a very different clinical position than one experiencing the same dizziness with no score improvement. The data shapes the decision to stay, adjust, or switch.
Patients using oral tablet programs should ask their prescribers whether PHQ-9 or a similar validated scale is being used, and how frequently. If it isn't, advocating for structured tracking is worthwhile — it protects patients from both under-treatment and unnecessary side-effect burden.
Key Takeaway for Oral Ketamine Users
If you're on oral ketamine tablets and not seeing symptom improvement after 3–4 weeks, that's a clinical signal — not a reason to quietly stop. Bring your side-effect log and any PHQ-9 scores to your provider and ask specifically about dose optimization before concluding that ketamine isn't working for you. The data suggest most discontinuation happens too early and for avoidable reasons.
Comparing Routes: When Tablets Make Sense, When They Don't
The Psychiatric Times analysis is a useful reminder that no single NMDA antagonist formulation is right for every patient — and that matching the route to the patient's tolerability profile, lifestyle, and severity of illness is itself a clinical skill worth exercising more deliberately.
Oral tablets are a strong first-line option for patients who are highly sensitive to dissociative effects, who have logistical barriers to clinic attendance, or who are early in ketamine treatment and want to start conservatively. They're also well-suited to maintenance dosing once an initial response has been established with a higher-bioavailability route.
Sublingual troches occupy a middle ground — higher absorption than swallowed tablets, home-based dosing, but with a more noticeable dissociative window. IV infusion remains the gold standard for acute crisis intervention and for patients who haven't responded to lower-bioavailability routes, precisely because it delivers the most reliable plasma levels with the sharpest clinical effect. Intranasal esketamine (Spravato) fills a specific niche as the only FDA-approved outpatient formulation, meaningful for patients whose insurance coverage or prescriber network makes it the most accessible option.
The takeaway from this emerging body of clinical guidance is not that one form of ketamine is best — it's that the decision should be made actively, documented carefully, and revisited regularly based on real outcome data. That's a shift from how ketamine has historically been managed, and for patients on oral tablets navigating this treatment on their own terms, it's an important signal that the clinical community is catching up to a more systematic approach.
Share